https://www.selleckchem.com/pr....oducts/rocilinostat-
Psoriasis is a chronic inflammatory disease affecting ~2-3% of the Australasian population. Therapeutic options include topical agents, phototherapy, systemic immunomodulators and biologic agents. Biologics present an acceptable short- and medium-term safety profile, derived mainly from randomised controlled trials (RCTs) and, however, may not represent real-world rates of adverse events (AEs). A retrospective, observational study of patients enrolled in The Australasian Psoriasis Registry from April 2008 to October 2018 w
Like
Comment
Share
